Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

294 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and safety of pyridoxal 5'-phosphate (MC-1) in high-risk patients undergoing coronary artery bypass graft surgery: the MEND-CABG II randomized clinical trial.
MEND-CABG II Investigators; Alexander JH, Emery RW Jr, Carrier M, Ellis SJ, Mehta RH, Hasselblad V, Menasche P, Khalil A, Cote R, Bennett-Guerrero E, Mack MJ, Schuler G, Harrington RA, Tardif JC. MEND-CABG II Investigators, et al. Among authors: mehta rh. JAMA. 2008 Apr 16;299(15):1777-87. doi: 10.1001/jama.299.15.joc80027. Epub 2008 Apr 1. JAMA. 2008. PMID: 18381567 Clinical Trial.
Outcomes associated with the use of secondary prevention medications after coronary artery bypass graft surgery.
Goyal A, Alexander JH, Hafley GE, Graham SH, Mehta RH, Mack MJ, Wolf RK, Cohn LH, Kouchoukos NT, Harrington RA, Gennevois D, Gibson CM, Califf RM, Ferguson TB Jr, Peterson ED; PREVENT IV Investigators. Goyal A, et al. Among authors: mehta rh. Ann Thorac Surg. 2007 Mar;83(3):993-1001. doi: 10.1016/j.athoracsur.2006.10.046. Ann Thorac Surg. 2007. PMID: 17307447 Clinical Trial.
A randomized, double-blind, placebo-controlled, multicenter study to evaluate the cardioprotective effects of MC-1 in patients undergoing high-risk coronary artery bypass graft surgery: MC-1 to Eliminate Necrosis and Damage in Coronary Artery Bypass Graft Surgery Trial (MEND-CABG) II--study design and rationale.
Mehta RH, Alexander JH, Emery R, Ellis SJ, Hasselblad V, Khalil A, Carrier M, Harrington RA, Tardif JC; MEND-CABG II Investigators. Mehta RH, et al. Am Heart J. 2008 Apr;155(4):600-8. doi: 10.1016/j.ahj.2008.01.002. Epub 2008 Feb 21. Am Heart J. 2008. PMID: 18371465 Clinical Trial.
Influence of preoperative renal dysfunction on one-year bypass graft patency and two-year outcomes in patients undergoing coronary artery bypass surgery.
Mehta RH, Hafley GE, Gibson CM, Harrington RA, Peterson ED, Mack MJ, Kouchoukos NT, Califf RM, Ferguson TB Jr, Alexander JH; Project of Ex-vivo Vein Graft Engineering via Transfection (PREVENT)-IV Investigators. Mehta RH, et al. J Thorac Cardiovasc Surg. 2008 Nov;136(5):1149-55. doi: 10.1016/j.jtcvs.2008.02.085. Epub 2008 Aug 27. J Thorac Cardiovasc Surg. 2008. PMID: 19026795 Free article.
Endoscopic versus open vein-graft harvesting in coronary-artery bypass surgery.
Lopes RD, Hafley GE, Allen KB, Ferguson TB, Peterson ED, Harrington RA, Mehta RH, Gibson CM, Mack MJ, Kouchoukos NT, Califf RM, Alexander JH. Lopes RD, et al. Among authors: mehta rh. N Engl J Med. 2009 Jul 16;361(3):235-44. doi: 10.1056/NEJMoa0900708. N Engl J Med. 2009. PMID: 19605828 Free article. Clinical Trial.
Saphenous vein grafts with multiple versus single distal targets in patients undergoing coronary artery bypass surgery: one-year graft failure and five-year outcomes from the Project of Ex-Vivo Vein Graft Engineering via Transfection (PREVENT) IV trial.
Mehta RH, Ferguson TB, Lopes RD, Hafley GE, Mack MJ, Kouchoukos NT, Gibson CM, Harrington RA, Califf RM, Peterson ED, Alexander JH; Project of Ex-vivo Vein Graft Engineering via Transfection (PREVENT) IV Investigators. Mehta RH, et al. Circulation. 2011 Jul 19;124(3):280-8. doi: 10.1161/CIRCULATIONAHA.110.991299. Epub 2011 Jun 27. Circulation. 2011. PMID: 21709060 Free PMC article. Clinical Trial.
Relationship between vein graft failure and subsequent clinical outcomes after coronary artery bypass surgery.
Lopes RD, Mehta RH, Hafley GE, Williams JB, Mack MJ, Peterson ED, Allen KB, Harrington RA, Gibson CM, Califf RM, Kouchoukos NT, Ferguson TB Jr, Alexander JH; Project of Ex Vivo Vein Graft Engineering via Transfection IV (PREVENT IV) Investigators. Lopes RD, et al. Among authors: mehta rh. Circulation. 2012 Feb 14;125(6):749-56. doi: 10.1161/CIRCULATIONAHA.111.040311. Epub 2012 Jan 11. Circulation. 2012. PMID: 22238227 Free PMC article.
Relationship between postoperative clopidogrel use and subsequent angiographic and clinical outcomes following coronary artery bypass grafting.
Williams JB, Lopes RD, Hafley GE, Ferguson TB Jr, Mack MJ, Gibson CM, Harrington RA, Peterson ED, Smith PK, Mehta RH, Alexander JH. Williams JB, et al. Among authors: mehta rh. J Thromb Thrombolysis. 2013 Nov;36(4):384-93. doi: 10.1007/s11239-013-0904-1. J Thromb Thrombolysis. 2013. PMID: 23543398 Free PMC article. Clinical Trial.
Edifoligide and long-term outcomes after coronary artery bypass grafting: PRoject of Ex-vivo Vein graft ENgineering via Transfection IV (PREVENT IV) 5-year results.
Lopes RD, Williams JB, Mehta RH, Reyes EM, Hafley GE, Allen KB, Mack MJ, Peterson ED, Harrington RA, Gibson CM, Califf RM, Kouchoukos NT, Ferguson TB, Lorenz TJ, Alexander JH. Lopes RD, et al. Among authors: mehta rh. Am Heart J. 2012 Sep;164(3):379-386.e1. doi: 10.1016/j.ahj.2012.05.019. Am Heart J. 2012. PMID: 22980305 Free PMC article. Clinical Trial.
294 results